How new weight loss drugs are impacting the food industry The increased use of GLP-1 drugs is impacting the food industry, reducing purchases in the near-term and shifting consumer habits
Quality assessment was performed using the Cochrane risk-of-bias tool
Here, Regeneron could chart a course for a better tolerated, but less efficacious, lean mass sparing weight loss combination with their anti-myostatin Route of Administration - Here, oral options might win if companies like Structure Therapeutics can solve the tolerability issues
Users remain on therapy for many months or years they need repeated lab checks, dose titration, short interval follow-ups and tight hand-offs between prescriber and pharmacy
Weight-related examples include exploring the potential for GLP-1s: Reduce the risk of cardiovascular events in adults with obesity and cardiovascular disease (CVD) Reduce complications from heart failure, sleep apnea, peripheral artery disease, and non-alcoholic steatohepatitis (NASH) in patients with obesity Researchers are also evaluating the effects of GLP-1s on diabetic retinopathy and even Alzheimers disease
Q: What role do Astaxanthin and Lycopene play in this product